Component

Human macrophage cytosolic calcium response

Human macrophage cytosolic calcium response

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Apigenin strongly reduced ATP-triggered cytosolic calcium mobilization in LPS-primed human macrophages.

    Apigenin → Human macrophage cytosolic calcium response Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_condition
    ATP without apigenin Apigenin before ATP · Apigenin Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_condition
    ATP without apigenin extracellular activation signal · ATP Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_condition
    ATP without apigenin prior priming · Lipopolysaccharide Condition belongs to the full experimental contrast; do not separate a joint intervention.
    experimental_contrast
    {"intervention": "Apigenin before ATP", "comparator": "ATP without apigenin", "endpoint": "Apigenin strongly reduced ATP-triggered cytosolic calcium mobilization in LPS-primed human macrophages.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "apigenin", "state": "Apigenin before ATP"}, {"entity_slug": "lipopolysaccharide", "state": "prior priming"}, {"entity_slug": "atp", "state": "extracellular activation signal"}]} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Fluo-4 imaging; 100 micromolar apigenin, 30 minutes, then ATP 3 mM.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    Apigenin strongly reduced ATP-triggered cytosolic calcium mobilization in LPS-primed human macrophages.
    primary_references
    Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. | https://pubmed.ncbi.nlm.nih.gov/39840045/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11746122/ | https://doi.org/10.3389/fimmu.2024.1497984
    source_locator
    Reviewed reference api-human-calcium; The responsible direct target was not established; do not assume a P2X7-only mechanism.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 340–346

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Fluo-4 imaging; 100 micromolar apigenin, 30 minutes, then ATP 3 mM. · Recorded from source · Recorded from source

    ### api-human-calcium Apigenin strongly reduced ATP-triggered cytosolic calcium mobilization in LPS-primed human macrophages. The responsible direct target was not established; do not assume a P2X7-only mechanism. Model and exposure: Fluo-4 imaging; 100 micromolar apigenin, 30 minutes, then ATP 3 mM. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. | 2024 | https://pubmed.ncbi.nlm.nih.gov/39840045/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11746122/ | https://doi.org/10.3389/fimmu.2024.1497984 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.